- As it awaits approval in several other markets, ChemChina has sought the U.S. antitrust regulator's approval for its planned $43B acquisition of Syngenta (NYSE:SYT).
- Sources close to the deal expect a green light soon, given the small revenue that ChemChina generates from the U.S. via Adama (OTCPK:ADAC), and its minor overlap with Syngenta products.
- SYT +2% premarket